News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Evotec AG Partners With Haplogen to Develop Drugs for Infectious Diseases
November 15, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
HAMBURG, Germany and VIENNA, Austria, Nov. 15, 2012 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) and Haplogen GmbH have signed a collaboration agreement to discover and develop small molecules against viral infectious diseases.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Europe
MORE ON THIS TOPIC
Layoffs
August biopharma layoffs impact just over 500, down 90% year over year
September 10, 2026
·
6 min read
·
Angela Gabriel
Layoff Tracker
Merck adds 53 to New Jersey chopping block
September 9, 2026
·
91 min read
·
BioSpace Editorial Staff
Manufacturing
Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision
September 9, 2026
·
2 min read
·
Nick Paul Taylor
FDA
Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease
September 9, 2026
·
1 min read
·
Jef Akst
